ViroGates A/S

Equities

VIRO

DK0061030574

Biotechnology & Medical Research

Market Closed - Nasdaq Copenhagen Other stock markets 08:50:00 10/06/2024 pm IST			5-day change	1st Jan Change
7.25 ^DKK	-5.23%		-7.05%	+20.43%

02/05	ViroGates A/S Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
15/04	Virogates A/S Announces the Outcome of Its Q-Submission Filing for Sobi®? Turbi Latex with the Us Food and Drug Administration	CI

ViroGates A/S Appoints John J. Reddington to its Board

November 25, 2013

ViroGates A/S announced that John J. Reddington, Chief Operation Officer of Cambridge Biomedical Inc., was appointed to the company's board of directors, increasing the number of board members to seven. John R. Reddington currently serves as COO of Cambridge Biomedical Inc.

Latest news about ViroGates A/S

ViroGates A/S Reports Earnings Results for the First Quarter Ended March 31, 2024	02/05	CI
Virogates A/S Announces the Outcome of Its Q-Submission Filing for Sobi®? Turbi Latex with the Us Food and Drug Administration	15/04	CI
ViroGates A/S Reports Earnings Results for the Full Year Ended December 31, 2023	21/03	CI
ViroGates A/S Provides Earnings Guidance for the Year 2024	21/12	CI
ViroGates A/S Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	09/11	CI
ViroGates A/S Announces Positive Results from a Randomized Controlled Clinical Trial on Supar-Guided Antibody Treatment in Sepsis	22/23/22	CI
ViroGates A/S Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	17/23/17	CI
Virogates Provides Earnings Guidance for 2023	17/23/17	CI
ViroGates A/S Announces an Agreement with Sobi for the Development of Suparnostic®	02/23/02	CI
ViroGates A/S Reports Earnings Results for the First Quarter Ended March 31, 2023	04/23/04	CI
ViroGates A/S Announces the Commercial Launch of suPARnostic POC+ Product	24/23/24	CI
ViroGates A/S Announces CE-IVD approval for suPARnostic® TurbiLatex on the Roche Diagnostics cobas® Pure and Pro instrument platforms	06/23/06	CI
Denmark's ViroGates Names New CFO	01/23/01	MT
ViroGates A/S Announces Chief Financial Officer Changes	01/23/01	CI
ViroGates A/S Revises Earnings Guidance for Full-Year 2022 and 2023	16/22/16	CI
ViroGates A/S Announces Executive Changes	06/22/06	CI
ViroGates A/S Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	10/22/10	CI
ViroGates A/S Announces the Publication of A New Study That Shows SsuPAR upar Causes Cardiovascular Disease	05/22/05	CI
ViroGates announces CE-IVD approval for suPARnostic® TurbiLatex on the Beckman Coulter AU5800 platform	23/22/23	CI
ViroGates A/S Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	18/22/18	CI
ViroGates A/S Provides Revenue Guidance for the Year 2022 and 2023	22/22/22	CI
ViroGates A/S Announces Board Changes	30/22/30	CI
ViroGates Announces the CE-Ivd Accreditation of Its Finger-Prick Blood-Testing Product, Suparnostic® Poc+	25/22/25	CI
ViroGates A/S Reports Earnings Results for the First Quarter Ended March 31, 2022	04/22/04	CI
ViroGates A/S Announces Board Changes	28/22/28	CI

Chart ViroGates A/S

Duration

Period

More charts

Company Profile

ViroGates A/S is a Denmark-based medical technology company. Its develops a product line suPARnostic, which measures the amount of amount of soluble urokinase Plasminogen Activator Receptor protein (suPAR) in human blood. The plasma level of suPAR reflects immune activation and is increased in such infectious diseases as HIV-1-infection, malaria, tuberculosis, Streptococcus pneumonia bacteraemia, sepsis, pneumococcal pneumonia and bacterial and viral CNS infection. Also, high suPAR levels are associated with increased inflammation, disease progression and risk of mortality. Thus, measuring suPAR levels serves as a marker to determine chances for survival upon hospital admission, as well as for monitoring for prevention of disease progression and earlier intervention time point. suPARnostic has two versions: Quantitative Point of Care Quick Triage test, which serves for patient triage in acute care, and Quantitative ELISA Assay that aims at clinical routine use.

Sector

Biotechnology & Medical Research

Calendar

15/08/2024 - Q2 2024 Earnings Release

More about the company

Income Statement Evolution

More financial data

Sector Bio Diagnostics & Testing

	1st Jan change	Capi.
VIROGATES A/S	+20.43%	7.14M
EXACT SCIENCES CORPORATION	-42.02%	7.92B
GUARDANT HEALTH, INC.	+11.13%	3.51B
IOVANCE BIOTHERAPEUTICS, INC.	-0.92%	2.18B
BGI GENOMICS CO., LTD.	-21.69%	1.97B
VERACYTE, INC.	-24.10%	1.58B
CAREDX, INC	+24.33%	792M
SEEGENE, INC.	-10.48%	690M
ADAPTIVE BIOTECHNOLOGIES CORPORATION	-28.78%	532M
CURIOX BIOSYSTEMS CO., LTD	-1.29%	303M

Bio Diagnostics & Testing